NASDAQ-listed Enveric Biosciences is merging with private psychedelics company, Magic Med Industries.
Psychedelics
MindMed Announces Launch of Collaboration with Nextage Therapeutics' Brain Targeting Liposome System
MindMed executes an MOU to access the drug delivery system of Israel-based Nextage Therapeutics.
Robust Capital Flows Continue For Private Psychedelics Companies
Public psychedelics companies have radically scaled-back capital raising due to low share prices. But institutional investors are still pumping large amounts of cash into private players.
Wesana Health Expands Research Leadership Team with Mark Wingertzahn, PhD as Chief Scientific Officer
Wesana's new Chief Scientific Officer has deep experience in the pharmaceutical industry with Pfizer and GSK.
Cybin Files its 12th Patent Further Strengthening IP Portfolio of Novel Psychedelic Molecules and Delivery Mechanisms
Cybin's 12th patent application further supports the company's novel molecule development.
MindMed Announces the Approval of Mescaline Study
Mindmed's drug R&D is broadening to include mescaline, after approval by a Swiss ethics committee of a new mescaline-based study.
Former Senate Majority Leader Tom Daschle Appointed Special Adviser to Field Trip Health Ltd.
Field Trip appoints a former high-ranking Democrat as a Special Advisor to the company.
Dr. Joel Raskin, a leader in psychiatry and neuroscience drug development, joins MINDCURE as Chief Medical Officer
MINDCURE announces the addition of Dr. Joel Raskin as its new Chief Medical Officer. Experience includes leadership positions with drug developer, Eli Lilly & Co.
Use of hallucinogens linked to risk seeking, emotional dysregulation in youth and college students
Hallucinogens benefit from somewhat greater acceptance than many other hard drugs, no doubt due in part to the fact that classic hallucinogens like LSD tend to be less harmful and are less likely to lead to physical dependence.
Texas Senate Advances Bill To Study Healing Potential Of Psychedelics Like Psilocybin and MDMA
A Texas Senate committee on Wednesday unanimously approved a House-passed bill that would require the state to conduct a study into the therapeutic potential of psychedelics like psilocybin and MDMA.
Novamind Opens Client Care Center to Support High Demand for Treatments
Novamind is adding a second Client Care Center as it expands its clinic network from four to eight locations.
More than 80% of Americans report one or more symptoms of depression, and many have turned to substances to cope with negative emotions during COVID-19 Pandemic, according to Field Trip Health’s First Annual “State of Mind” Survey
Over 80% of Americans are exhibiting symptoms of depression related to the COVID-19 pandemic. Nearly 1 in 4 Americans have experienced suicidal or self-destructive thoughts.
Politicians And Regulators Require Re-Education On Drugs
The Psychedelic Drug Revolution has begun. Standing in the way are politicians and regulators, saddled with archaic anti-drug phobias. They need to be educated.
A single dose of psilocybin has a lasting therapeutic effect on migraine headache, according to a new placebo-controlled study
Scientists have started to investigate whether psilocybin, the primary substance responsible for the psychedelic effects of “magic” mushrooms, could be helpful to those who suffer from migraine headache.
Cybin Granted IRB Approval for Phase II Clinical Trials of its Sublingual Psilocybin Formulation for the Treatment of Major Depressive Disorder
Cybin announces approval to enter its Phase IIa clinical study and defines the scope of the clinical trial.